Report Detail

Request for Sample of this report

Pharma & Healthcare Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-Obesity Prescription Drugs Market 2018, Forecast to 2023

  • RnM2733513
    • |
  • 07 January, 2019
    • |
  • Global
    • |
  • 130 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.

Scope of the Report:
This report focuses on the Anti-Obesity Prescription Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Anti-Obesity Prescription Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
F Hoffmann La Roche Ltd
Orexigen Therapeutics, Inc
Novo Nordisk A/s
Arena Pharmaceuticals, Inc
Glaxosmithkline
Vivus, Inc
Boehringer Ingelheim
Alizyme

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide

Market Segment by Applications, can be divided into
Pediatric
Adult

There are 15 Chapters to deeply display the global Anti-Obesity Prescription Drugs market.
Chapter 1, to describe Anti-Obesity Prescription Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Obesity Prescription Drugs, with sales, revenue, and price of Anti-Obesity Prescription Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Obesity Prescription Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Obesity Prescription Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Obesity Prescription Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


Table of Contents

    1 Market Overview

    • 1.1 Anti-Obesity Prescription Drugs Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Orlistat
      • 1.2.2 Phentermine and Topiramate
      • 1.2.3 Bupropion and Naltrexone
      • 1.2.4 Lorcaserin
      • 1.2.5 Liraglutide
    • 1.3 Market Analysis by Applications
      • 1.3.1 Pediatric
      • 1.3.2 Adult
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2013-2023)
        • 1.4.1.2 Canada Market States and Outlook (2013-2023)
        • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2013-2023)
        • 1.4.2.2 France Market States and Outlook (2013-2023)
        • 1.4.2.3 UK Market States and Outlook (2013-2023)
        • 1.4.2.4 Russia Market States and Outlook (2013-2023)
        • 1.4.2.5 Italy Market States and Outlook (2013-2023)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2013-2023)
        • 1.4.3.2 Japan Market States and Outlook (2013-2023)
        • 1.4.3.3 Korea Market States and Outlook (2013-2023)
        • 1.4.3.4 India Market States and Outlook (2013-2023)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
        • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
        • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
        • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 F Hoffmann La Roche Ltd
      • 2.1.1 Business Overview
        • 2.1.1.1 F Hoffmann La Roche Ltd Description
        • 2.1.1.2 F Hoffmann La Roche Ltd Headquarter, Main Business and Finance Overview
      • 2.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Introduction
        • 2.1.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.1.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.1.3.1 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.1.3.2 Global F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.2 Orexigen Therapeutics, Inc
      • 2.2.1 Business Overview
        • 2.2.1.1 Orexigen Therapeutics, Inc Description
        • 2.2.1.2 Orexigen Therapeutics, Inc Headquarter, Main Business and Finance Overview
      • 2.2.2 Orexigen Therapeutics, Inc Anti-Obesity Prescription Drugs Product Introduction
        • 2.2.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.2.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.2.3 Orexigen Therapeutics, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.2.3.1 Orexigen Therapeutics, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.2.3.2 Global Orexigen Therapeutics, Inc Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.3 Novo Nordisk A/s
      • 2.3.1 Business Overview
        • 2.3.1.1 Novo Nordisk A/s Description
        • 2.3.1.2 Novo Nordisk A/s Headquarter, Main Business and Finance Overview
      • 2.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Introduction
        • 2.3.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.3.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.3.3.1 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.3.3.2 Global Novo Nordisk A/s Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.4 Arena Pharmaceuticals, Inc
      • 2.4.1 Business Overview
        • 2.4.1.1 Arena Pharmaceuticals, Inc Description
        • 2.4.1.2 Arena Pharmaceuticals, Inc Headquarter, Main Business and Finance Overview
      • 2.4.2 Arena Pharmaceuticals, Inc Anti-Obesity Prescription Drugs Product Introduction
        • 2.4.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.4.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.4.3 Arena Pharmaceuticals, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.4.3.1 Arena Pharmaceuticals, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.4.3.2 Global Arena Pharmaceuticals, Inc Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.5 Glaxosmithkline
      • 2.5.1 Business Overview
        • 2.5.1.1 Glaxosmithkline Description
        • 2.5.1.2 Glaxosmithkline Headquarter, Main Business and Finance Overview
      • 2.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Introduction
        • 2.5.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.5.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.5.3.1 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.5.3.2 Global Glaxosmithkline Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.6 Vivus, Inc
      • 2.6.1 Business Overview
        • 2.6.1.1 Vivus, Inc Description
        • 2.6.1.2 Vivus, Inc Headquarter, Main Business and Finance Overview
      • 2.6.2 Vivus, Inc Anti-Obesity Prescription Drugs Product Introduction
        • 2.6.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.6.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.6.3 Vivus, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.6.3.1 Vivus, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.6.3.2 Global Vivus, Inc Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.7 Boehringer Ingelheim
      • 2.7.1 Business Overview
        • 2.7.1.1 Boehringer Ingelheim Description
        • 2.7.1.2 Boehringer Ingelheim Headquarter, Main Business and Finance Overview
      • 2.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Introduction
        • 2.7.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.7.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.7.3.1 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.7.3.2 Global Boehringer Ingelheim Anti-Obesity Prescription Drugs Market Share in 2017
    • 2.8 Alizyme
      • 2.8.1 Business Overview
        • 2.8.1.1 Alizyme Description
        • 2.8.1.2 Alizyme Headquarter, Main Business and Finance Overview
      • 2.8.2 Alizyme Anti-Obesity Prescription Drugs Product Introduction
        • 2.8.2.1 Anti-Obesity Prescription Drugs Production Bases, Sales Regions and Major Competitors
        • 2.8.2.2 Anti-Obesity Prescription Drugs Product Information
      • 2.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.8.3.1 Alizyme Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.8.3.2 Global Alizyme Anti-Obesity Prescription Drugs Market Share in 2017

      3 Global Anti-Obesity Prescription Drugs Market Competition, by Manufacturer

      • 3.1 Global Anti-Obesity Prescription Drugs Sales and Market Share by Manufacturer (2016-2017)
      • 3.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Manufacturer (2016-2017)
      • 3.3 Global Anti-Obesity Prescription Drugs Price by Manufacturer (2016-2017)
      • 3.4 Market Concentration Rate
        • 3.4.1 Top 3 Anti-Obesity Prescription Drugs Manufacturer Market Share in 2017
        • 3.4.2 Top 5 Anti-Obesity Prescription Drugs Manufacturer Market Share in 2017
      • 3.5 Market Competition Trend

      4 Global Anti-Obesity Prescription Drugs Market Analysis by Regions

      • 4.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Regions
        • 4.1.1 Global Anti-Obesity Prescription Drugs Sales by Regions (2013-2018)
        • 4.1.2 Global Anti-Obesity Prescription Drugs Revenue by Regions (2013-2018)
      • 4.2 North America Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2013-2018)
      • 4.3 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2013-2018)
      • 4.4 Asia-Pacific Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2013-2018)
      • 4.5 South America Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2013-2018)
      • 4.6 Middle East and Africa Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2013-2018)

      5 North America Anti-Obesity Prescription Drugs by Countries, Type, Application and Manufacturers

      • 5.1 North America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
        • 5.1.1 North America Anti-Obesity Prescription Drugs Sales by Countries (2013-2018)
        • 5.1.2 North America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2018)
        • 5.1.3 United States Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 5.1.4 Canada Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 5.1.5 Mexico Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
      • 5.2 North America Anti-Obesity Prescription Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
        • 5.2.1 North America Anti-Obesity Prescription Drugs Sales by Manufacturers (2016-2017)
        • 5.2.2 North America Anti-Obesity Prescription Drugs Revenue by Manufacturers (2016-2017)
      • 5.3 North America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 5.3.1 North America Anti-Obesity Prescription Drugs Sales and Sales Share by Type (2013-2018)
        • 5.3.2 North America Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2013-2018)
      • 5.4 North America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Application (2013-2018)
        • 5.4.1 North America Anti-Obesity Prescription Drugs Sales and Sales Share by Application (2013-2018)
        • 5.4.2 North America Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2013-2018)

      6 Europe Anti-Obesity Prescription Drugs by Countries, Type, Application and Manufacturers

      • 6.1 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
        • 6.1.1 Europe Anti-Obesity Prescription Drugs Sales by Countries (2013-2018)
        • 6.1.2 Europe Anti-Obesity Prescription Drugs Revenue by Countries (2013-2018)
        • 6.1.3 Germany Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 6.1.4 UK Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 6.1.5 France Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 6.1.6 Russia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 6.1.7 Italy Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
      • 6.2 Europe Anti-Obesity Prescription Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
        • 6.2.1 Europe Anti-Obesity Prescription Drugs Sales by Manufacturers (2016-2017)
        • 6.2.2 Europe Anti-Obesity Prescription Drugs Revenue by Manufacturers (2016-2017)
      • 6.3 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 6.3.1 Europe Anti-Obesity Prescription Drugs Sales and Sales Share by Type (2013-2018)
        • 6.3.2 Europe Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2013-2018)
      • 6.4 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Application (2013-2018)
        • 6.4.1 Europe Anti-Obesity Prescription Drugs Sales and Sales Share by Application (2013-2018)
        • 6.4.2 Europe Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2013-2018)

      7 Asia-Pacific Anti-Obesity Prescription Drugs by Countries, Type, Application and Manufacturers

      • 7.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
        • 7.1.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales by Countries (2013-2018)
        • 7.1.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue by Countries (2013-2018)
        • 7.1.3 China Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 7.1.4 Japan Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 7.1.5 Korea Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 7.1.6 India Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 7.1.7 Southeast Asia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
      • 7.2 Asia-Pacific Anti-Obesity Prescription Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
        • 7.2.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales by Manufacturers (2016-2017)
        • 7.2.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue by Manufacturers (2016-2017)
      • 7.3 Asia-Pacific Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 7.3.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales and Sales Share by Type (2013-2018)
        • 7.3.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2013-2018)
      • 7.4 Asia-Pacific Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Application (2013-2018)
        • 7.4.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales and Sales Share by Application (2013-2018)
        • 7.4.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2013-2018)

      8 South America Anti-Obesity Prescription Drugs by Countries, Type, Application and Manufacturers

      • 8.1 South America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
        • 8.1.1 South America Anti-Obesity Prescription Drugs Sales by Countries (2013-2018)
        • 8.1.2 South America Anti-Obesity Prescription Drugs Revenue by Countries (2013-2018)
        • 8.1.3 Brazil Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 8.1.4 Argentina Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 8.1.5 Colombia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
      • 8.2 South America Anti-Obesity Prescription Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
        • 8.2.1 South America Anti-Obesity Prescription Drugs Sales by Manufacturers (2016-2017)
        • 8.2.2 South America Anti-Obesity Prescription Drugs Revenue by Manufacturers (2016-2017)
      • 8.3 South America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 8.3.1 South America Anti-Obesity Prescription Drugs Sales and Sales Share by Type (2013-2018)
        • 8.3.2 South America Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2013-2018)
      • 8.4 South America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Application (2013-2018)
        • 8.4.1 South America Anti-Obesity Prescription Drugs Sales and Sales Share by Application (2013-2018)
        • 8.4.2 South America Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2013-2018)

      9 Middle East and Africa Anti-Obesity Prescription Drugs by Countries, Type, Application and Manufacturers

      • 9.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
        • 9.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Countries (2013-2018)
        • 9.1.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Countries (2013-2018)
        • 9.1.3 Saudi Arabia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 9.1.4 UAE Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 9.1.5 Egypt Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 9.1.6 Nigeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
        • 9.1.7 South Africa Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
      • 9.2 Middle East and Africa Anti-Obesity Prescription Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
        • 9.2.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Manufacturers (2016-2017)
        • 9.2.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue by Manufacturers (2016-2017)
      • 9.3 Middle East and Africa Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 9.3.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales and Sales Share by Type (2013-2018)
        • 9.3.1 Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2013-2018)
      • 9.4 Middle East and Africa Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Application (2013-2018)
        • 9.4.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales and Sales Share by Application (2013-2018)
        • 9.4.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2013-2018)

      10 Global Anti-Obesity Prescription Drugs Market Segment by Type

      • 10.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
        • 10.1.1 Global Anti-Obesity Prescription Drugs Sales and Market Share by Type (2013-2018)
        • 10.1.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2013-2018)
      • 10.2 Orlistat Sales Growth and Price
        • 10.2.1 Global Orlistat Sales Growth (2013-2018)
        • 10.2.2 Global Orlistat Price (2013-2018)
      • 10.3 Phentermine and Topiramate Sales Growth and Price
        • 10.3.1 Global Phentermine and Topiramate Sales Growth (2013-2018)
        • 10.3.2 Global Phentermine and Topiramate Price (2013-2018)
      • 10.4 Bupropion and Naltrexone Sales Growth and Price
        • 10.4.1 Global Bupropion and Naltrexone Sales Growth (2013-2018)
        • 10.4.2 Global Bupropion and Naltrexone Price (2013-2018)
      • 10.5 Lorcaserin Sales Growth and Price
        • 10.5.1 Global Lorcaserin Sales Growth (2013-2018)
        • 10.5.2 Global Lorcaserin Price (2013-2018)
      • 10.6 Liraglutide Sales Growth and Price
        • 10.6.1 Global Liraglutide Sales Growth (2013-2018)
        • 10.6.2 Global Liraglutide Price (2013-2018)

      11 Global Anti-Obesity Prescription Drugs Market Segment by Application

      • 11.1 Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2013-2018)
      • 11.2 Pediatric Sales Growth (2013-2018)
      • 11.3 Adult Sales Growth (2013-2018)

      12 Anti-Obesity Prescription Drugs Market Forecast (2018-2023)

      • 12.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2018-2023)
      • 12.2 Anti-Obesity Prescription Drugs Market Forecast by Regions (2018-2023)
        • 12.2.1 North America Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
        • 12.2.2 Europe Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
        • 12.2.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
        • 12.2.4 South America Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
        • 12.2.5 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
      • 12.3 Anti-Obesity Prescription Drugs Market Forecast by Type (2018-2023)
        • 12.3.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Type (2018-2023)
        • 12.3.2 Global Anti-Obesity Prescription Drugs Market Share Forecast by Type (2018-2023)
      • 12.4 Anti-Obesity Prescription Drugs Market Forecast by Application (2018-2023)
        • 12.4.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Application (2018-2023)
        • 12.4.2 Global Anti-Obesity Prescription Drugs Market Share Forecast by Application (2018-2023)

      13 Sales Channel, Distributors, Traders and Dealers

      • 13.1 Sales Channel
        • 13.1.1 Direct Marketing
        • 13.1.2 Indirect Marketing
        • 13.1.3 Marketing Channel Future Trend
      • 13.2 Distributors, Traders and Dealers

      14 Research Findings and Conclusion

        15 Appendix

        • 15.1 Methodology

      Summary:
      Get latest Market Research Reports on Anti-Obesity Prescription Drugs . Industry analysis & Market Report on Anti-Obesity Prescription Drugs is a syndicated market report, published as Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-Obesity Prescription Drugs Market 2018, Forecast to 2023. It is complete Research Study and Industry Analysis of Anti-Obesity Prescription Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$4,880.00
      		$7,320.00
      		$9,760.00
      		3,928.40
      		5,892.60
      		7,856.80
      		4,718.96
      		7,078.44
      		9,437.92
      		739,759.20
      		1,109,638.80
      		1,479,518.40
      		427,878.40
      		641,817.60
      		855,756.80
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo